Navigation Links
Second-line CML drugs evoke faster response than front-line therapy
Date:12/7/2009

Administration for patients who can't tolerate imatinib or whose CML resists the drug.

The dasatinib trial has enrolled 62 patients with previously untreated early stage CML taking either 50 mg twice daily or 100 mg once a day. Among 50 patients followed for at least three months, 49 (98 percent) achieved complete cytogenetic response. Major molecular response, a more stringent measure of remission, was reached in 35 patients (70 percent) with five (10 percent) achieving complete molecular response.

The researchers have dropped the twice daily arm of the trial, keeping the 100 mg once a day arm open because it has produced higher rates of major molecular response with fewer side effects.

The nilotinib trial has enrolled 65 patients with the 400mg twice daily dose producing complete cytogenetic responses in 50 of 51 patients (98 percent) followed for at least three months. Major molecular response has been achieved in 32 patients (63 percent) with 12 (24 percent) achieving complete molecular response.

All patients in both trials are alive, and enrollment continues. Side effects are being closely monitored and some patients in each trial had their treatment reduced or temporarily interrupted because of toxicities. Side effects are manageable and similar to those seen for imatinib, Cortes said.

Early results for both comparisons

Months on therapy Percent of patients with Complete Cytogenetic Response
Dasatinib Imatinib 400mg Imatinib 800mg
3 82 37 63
6 94 54 85
12 98 65 89
18 89 67 89
24 84 67 88
30 83 67 89

Months on therapy Percent of patients with Complete Cytogenetic Response (Number of valuable patients)
Nilotinib Imatinib 400mg Imatinib 800mg
3 90 37 63
6 96 54 85
12 97 65 89
18 93 67 89
24 93 67 88
30 92 67 89


'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-516-4855
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. AHF/India Cares Provides Second-line AIDS Drugs to Activists in India
2. Activist Groups Plea to Indian Prime Minister: Rollout Second-Line AIDS Treatment!
3. Simvastatin Leads Pfizers Lipitor in Second-Line Patient Share for the Treatment of Dyslipidemia
4. More Patients Receive Diovan As A First- Or Second-Line Therapy Compared With Cozaar or Avapro
5. Seroquels First- and Second-Line Patient Share Has Grown Since Last Years Analysis of Prescribing Trends in Bipolar Disorder
6. AstraZeneca Submits New Drug Applications for ZACTIMA(TM) in Second-Line Advanced Non-Small Cell Lung Cancer
7. New review suggests caution on drugs to raise good cholesterol
8. Can cancer drugs combine forces?
9. Study provides hope that some transplant patients could live free of antirejection drugs
10. Study provides hope that some transplant patients could live free of anti-rejection drugs
11. RA Drugs Linked to Slight Skin Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... In honor of National Breast Cancer Awareness ... courageous battles, Incredible Veins, Body & Skin is offering ... Cynosure. , “For cancer patients who receive radiation ... on their skin to accurately aim the radiation on ... survivors, they decide to have their tattoo removed as ...
(Date:9/30/2014)... Every New Year begins with a Resolution that will soon ... of effort, however most are out of mind in 30. Why? ... Instead of "spend more time with children", try something easy to ... Without a reminder, daily life gets in the way and efforts ... 3. Goals out of sight equals goals out of mind. ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 From October ... be exhibiting at the 2014 SHSMD Connections Annual Conference ... for Healthcare Strategy & Market Development (SHSMD) is proud ... marketing, public relations and communications, and strategic planning professionals ... About SHSMD Connections , The conference is a ...
(Date:9/30/2014)... Albany, IN (PRWEB) September 30, 2014 ... Dr. Ron Receveur encourages all persons who have received ... disease in a recent blog post. , The post, ... those with dental implants that if they don’t brush ... the same way people lose their natural teeth: the ...
(Date:9/30/2014)... Chicago, IL (PRWEB) September 30, 2014 ... cannabinoid clash,” opened Bryan W. Brickner, “and it’s ... Sleep Political Cannabinoid Science , new on the ... sleep research from the National Institutes of Health ... articles regarding: de-homeostatic sleep disturbances, REM transitions, aging ...
Breaking Medicine News(10 mins):Health News:Incredible Veins, Body & Skin Takes A Stand Against Breast Cancer With PicoSure® By Cynosure 2Health News:MMS, Inc. (Medical Marketing Service) to Attend the 2014 SHSMD Connections Annual Conference in October 2Health News:All on Four Dental Implants Dentist Writes Blog on Preventing Gum Disease 2Health News:All on Four Dental Implants Dentist Writes Blog on Preventing Gum Disease 3Health News:Homeostasis: Publius’ Sleep Political Cannabinoid Science ~ New on the Bryan William Brickner Blog 2
... at Children,s National Medical Center and the ... the results of the first successful application of "multiple ... muscular dystrophy in an animal larger than a ... "DNA band-aids" to skip over the parts of the ...
... SAN DIEGO, March 16 Gen-Probe Incorporated (Nasdaq: ... (AIM: TED) approved the acquisition of Tepnel by Gen-Probe by ... London earlier today.More than 99% of Tepnel shareholders voted in ... 30, 2009 and is structured as a "scheme of arrangement" ...
... Office Building Project Provides State-of-the-Art Healthcare for Rural ... Roads Ventures (HRV), a community development investment firm, ... program to provide equity and debt financing for ... rural communities in Virginia providing successful solutions to ...
... products contain allergens no matter what ingredients are listed, study ... number of food products with a "may contain" label actually ... of foods products without such a claim also contain allergens, ... came from smaller companies, noted the authors of a study ...
... March 16 /PRNewswire-Asia-FirstCall/ -- China Yongxin Pharmaceuticals, Inc. ... Board: CYXN), a leading manufacturer, distributor and retailer ... it has rolled out its Electronic Diagnosis System ... Changchun, Jilin. In order to ensure safety of ...
... adventure series results from a life of creative ... Ohio, March 16 Randy Patterson has spent ... a deadly, aggressive and extremely rare cancer called ... nine grueling spinal taps, mounting financial debt, and ...
Cached Medicine News:Health News:First treatment for muscular dystrophy in sight: Scientists successfully harness exon-skipping 2Health News:First treatment for muscular dystrophy in sight: Scientists successfully harness exon-skipping 3Health News:Tepnel Shareholders Approve Acquisition by Gen-Probe 2Health News:Tepnel Shareholders Approve Acquisition by Gen-Probe 3Health News:Tepnel Shareholders Approve Acquisition by Gen-Probe 4Health News:Hampton Roads Ventures Tackles U.S. Healthcare Crisis Community by Community 2Health News:Food Allergy Labeling Not Always Accurate 2Health News:Food Allergy Labeling Not Always Accurate 3Health News:China Yongxin Pharmaceuticals Inc. Launches Electronic Diagnosis System in its Changchun Drugstores 2Health News:China Yongxin Pharmaceuticals Inc. Launches Electronic Diagnosis System in its Changchun Drugstores 3Health News:Trinadgey Launches to Sci-Fi Lovers via New Online Portal Trinadgey.com 2
(Date:9/30/2014)... BETHESDA, Md. , Sept. 30, 2014 ... "Company") (Nasdaq: CHDX ) today announced the ... ("Healthy Harmony") for $24.00 per share in cash.  Healthy ... (Group) Co., Ltd. ("Fosun") and Ms. Roberta Lipson ... previously announced merger agreement was adopted by Chindex,s stockholders ...
(Date:9/29/2014)... PARIS , Sept. 30, 2014 /PRNewswire/ ... SAN and NYSE: SNY) today announced that a Phase ... blocks IL-4 and IL-13 signaling, met all primary and ... nasal polyps (CSwNP) who did not respond to intranasal ... of dupilumab for use in the treatment of another ...
(Date:9/29/2014)... CHICAGO , Sept. 29, 2014 ... clinical trials are conducted according to good clinical ... the HOPA Investigational Drug Service Best Practice Standards, ... best practice standards and guidance for pharmacists and ... Drug Service Best Practice Standards emphasizes the critical ...
Breaking Medicine Technology:Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 2Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 3Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 4Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 5Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 2Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 3Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 4Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 5Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 6Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 7HOPA Introduces First Investigational Drug Service Best Practice Standards For Institutions And Infusion Clinics 2HOPA Introduces First Investigational Drug Service Best Practice Standards For Institutions And Infusion Clinics 3
... , SAN DIEGO, Oct. 7 CareFusion Corporation (NYSE: CFN ... fiscal 2010 on Tuesday, Nov. 10 following the close of trading ... a webcast and conference call on Nov. 10 at 2:00 pm ... its first quarter, ended on Sep. 30, 2009. To access the ...
... Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce ... be demonstrated at the 95th Annual American College of ... Illinois. During the Breast Ductoscopy for the General Surgeon ... to hands-on skill stations that will provide the core ...
Cached Medicine Technology:CareFusion Will Host An Earnings Conference Call on November 10, 2009 to Discuss the Results for the First Quarter of Fiscal 2010 2Solos Endoscopy, Inc.'s MammoView(TM) Product Line to be Demonstrated at the 95th Annual American College of Surgeons Clinical Congress 2
For the qualitative detection of group A streptococcal antigen from throat swabs....
For the measurement of vaginal pH as part of a self examination programme to help reduce the risk of pre-term birth...
For the qualitative detection of human Chorionic Gonadotrophin (hCG) in urine specimens...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Medicine Products: